smith and nephew acquisition

smith and nephew acquisition


Certain marks registered US Patent and Trademark Office. ◊Trademark of Smith & Nephew. Any forward-looking statement is based on information available to Smith+Nephew as of the date of the statement. Smith+Nephew expands in higher-growth extremities segment through planned acquisition of Integra LifeSciences' Extremity Orthopaedics business. For example, statements regarding expected revenue growth and trading margins, market trends and our product pipeline are forward-looking statements. The acquisition is expected to complete around the end of 2020, subject to the satisfaction of customary conditions including consultation with employee representative bodies. The business generated revenue of $90 million in 2019 and traded at a small loss. The portfolio is highly complementary to Smith+Nephew's existing orthopaedics offering, in particular providing entry into the shoulder replacement and foot and ankle segments. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. The full portfolio includes devices, implants, and instruments which provide for shoulder replacement as well as reconstruction of bone in the hand, wrist and elbow (Upper Extremity) and foot and ankle (Lower Extremity). This document may contain forward-looking statements that may or may not prove accurate. For Smith+Nephew, these factors include: risks related to the impact of COVID-19, such as the depth and longevity of its impact, government actions and other restrictive measures taken in response, material delays and cancellations of elective procedures, reduced procedure capacity at medical facilities, restricted access for sales representatives to medical facilities, or our ability to execute business continuity plans as a result of COVID-19; economic and financial conditions in the markets we serve, especially those affecting health care providers, payers and customers (including, without limitation, as a result of COVID-19); price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls or other problems with quality management systems or failure to comply with related regulations; litigation relating to patent or other claims; legal compliance risks and related investigative, remedial or enforcement actions; disruption to our supply chain or operations or those of our suppliers (including, without limitation, as a result of COVID-19); competition for qualified personnel; strategic actions, including acquisitions and dispositions, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. This document may contain forward-looking statements that may or may not prove accurate.

The Extremity Orthopaedics R&D pipeline includes a next-generation shoulder replacement system, which is expected to be ready for full commercial launch in 2022. Phrases such as "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate", "expect", "target", "consider" and similar expressions are generally intended to identify forward-looking statements. The Extremity Orthopaedics R&D pipeline includes a next-generation shoulder replacement system, which is expected to be ready for full commercial launch in 2022. 29 September 2020. All written or oral forward-looking statements attributable to Smith+Nephew are qualified by this caution. Smith & Nephew plc (LSE:SN, NYSE:SNN), the global medical technology business, announces that it has agreed to acquire Osiris Therapeutics, Inc. (NASDAQ: OSIR), a fast growing company delivering regenerative medicine products, including skin, bone graft and articular cartilage substitutes, for $19.00 per share in cash, representing a total equity value of approximately … This strategic acquisition represents a significant opportunity to strengthen Smith+Nephew's position in a high-value area and allows us to offer a leading extremities portfolio to customers.". Smith & Nephew Plc. For more information, please read our Privacy Policy. Smith+Nephew is a constituent of the FTSE100 (LSE:SN, NYSE:SNN). For Smith & Nephew, these factors include: economic and financial conditions in the markets we serve, especially those affecting health care providers, payers and customers; price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls or other problems with quality management systems or failure to comply with related regulations; litigation relating to patent or other claims; legal compliance risks and related investigative, remedial or enforcement actions; disruption to our supply chain or operations or those of our suppliers; competition for qualified personnel; strategic actions, including acquisitions and dispositions, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Announced Date Feb 26, 2020. All written or oral forward-looking statements attributable to Smith & Nephew are qualified by this caution. Smith+Nephew is a portfolio medical technology business that exists to restore people’s bodies and their self-belief by using technology to take the limits off living. This website uses cookies to help you get the most out of your experience during your visit, and we can improve the content served to you by collecting statistical information.

This website uses cookies to help you get the most out of your experience during your visit, and we can improve the content served to you by collecting statistical information. The acquisition supports Smith+Nephew's strategy to invest in higher-growth segments. The business is expected to deliver double-digit revenue growth and be slightly dilutive to trading profit in 2021 and 2022. Acquiring Organization: Smith & Nephew Smith and Nephew is a manufactures and markets orthopedic devices, sports medicine and ENT technologies. The focused extremities commercial channel includes a specialised sales force and distributors, predominantly in the US as well as Canada and Europe. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. For the latest news and information about Integra and its products, please visit www.integralife.com. Please refer to the documents that Smith & Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith & Nephew's most recent annual report on Form 20-F, for a discussion of certain of these factors. The terms ‘Group’ and ‘Smith+Nephew’ are used to refer to Smith & Nephew plc and its consolidated subsidiaries, unless the context requires otherwise. Investors Andrew Swift Smith & Nephew +44 (0) 20 7960 2285 Media Charles Reynolds Smith & Nephew +44 (0) 1923 477314 Ben Atwell / Andrew Ward FTI Consulting +44 (0) 20 3727 1000

We are excited for the opportunities ahead as we continue to advance orthopaedic innovations for our customers and improve patient outcomes.". Integra LifeSciences is a global leader in regenerative technologies, neurosurgical and extremity orthopedic solutions dedicated to limiting uncertainty for clinicians, so they can focus on providing the best patient care. Skip Kiil, President, Global Orthopaedics at Smith+Nephew, said: "Integra's Extremity Orthopaedics business is an established global player in the rapidly growing extremities segment, including total shoulder replacement, and has a well-regarded specialised sales channel and a strong pipeline of new products. The acquisition is expected to accelerate growth from Smith & Nephew’s Advanced Wound Management franchise. Smith+Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith+Nephew's expectations. It is expected that around 300 employees will join Smith+Nephew on completion.

Smith & Nephew is a portfolio medical technology business with leadership positions in Orthopaedics, Advanced Wound Management and Sports Medicine. For the latest news and information about Integra and its products, please visit www.integralife.com .

The Return on Invested Capital (ROIC) is expected to meet or exceed our Weighted Average Cost of Capital (WACC) by the fifth year. Terms and conditions relating to the use and distribution of this information may apply. All written or oral forward-looking statements attributable to Smith+Nephew are qualified by this caution. Smith+Nephew is a portfolio medical technology business that exists to restore people's bodies and their self-belief by using technology to take the limits off living.

Top Gear All Seasons, Top 100 Richest Countries In The World, Call To Action Speech, Iphone 4s Screen Size, Kirsten Dunst Wedding, Ring Doorbell Event History Not Working, Goulburn Valley Brand, Logistics Of Moving To Europe, Peru National Football Team Schedule, Islands In The Stream (karaoke Male Part), George Groves Career Earnings, Charley Patton Grave, Hope Vs Belief, Nest Camera Installation, Humboldt University Berlin Course Catalogue, Johnny Cade, Did Kate Hudson Really Dance On Glee, Internet Speed Calculator, Sergio Aguero Net Worth, Jnj Stock Dividend 2019, Black Wolves Lacrosse Record, A Royal Night Out Streaming, Steinbeis University Berlin World Ranking, Aladin Astronomy, Colombia And Brazil Similarities, Fifa 2010 World Cup Game, Eleanor Powell Ford, Flinders Uni Vacancy, Jon Feliciano Injury, Shaftesbury Avenue, Apollo 13 Explosion, Tak Stock, Thomas Kail, Scouts Guide To The Zombie Apocalypse Streaming, Seemore Putters On Tour, Liona Boyd The First Lady Of Guitar, Hurts Like Heaven Meaning, Wlodarczyk Pronunciation, Crocs Shops, Bob Saget: Zero To Sixty, Animal Parks Near Me, Country Life For Half The Price Suffolk, Is Aubameyang The Son Of Gabon President, Floyd Mayweather Clothing, Simplisafe Wireless Doorbell, Lindsey Graham Finances, Courtney Thorne-smith Wiki, God's Silence In The Bible, Imperfection Evanescence Lyrics, Paul Wahlberg Nephews, Paul Fix Net Worth, Thomas Skinner, Biggest Stadium In World, People's Armed Police Hong Kong, Carefusion Tech Support, Rain, Steam And Speed -- The Great Western Railway, Marc-andre Fleury Injury, Home Goods Pillows, Cast Of Scrooged 1984, Shinji Okazaki Salary, Pope Pius Vi, Nico Cortez, Cost To Retire In Barcelona, James Conner Fantasy Football, Toy Story Toons: Small Fry, Kenneth Branagh Romeo And Juliet Full Play, Iran Football Team Ranking, + 18moreBest Dinners With KidsKass Kebab House, Istanbul Kebabs, And More, Penn State Football 2019, Noah Munck Net Worth, Sonny West Height, Evgeni Malkin Instagram, Shelta Language Words, Macquarie University Mba Ranking, Face Id Android, Powers Boothe Avengers, Frances Meaning In English, Paul Barnes, Clemente Rodríguez, Abbott Laboratories 100 Abbott Park Rd North Chicago Il 60064, Abt Dividend, Knowledge Of Performance, Kasper Dolberg Nice, Bukayo Saka Stats 2020, Doom 3 Switch, Blue Ivy Age, Dominic Holland Net Worth, The War Of The Roses, Emma Heming Willis Net Worth, Joe Flacco Family, Florida Panthers Stanley Cup, Tal Farlow Gibson, How To Manage Landslide, Mark Seymour Net Worth, Flying Bison Brewing Company, Political Advisor Salary, Resistance Physics Formula,

No Comments

Post A Comment

Register